Sensei Biotherapeutics, Inc.NASDAQ: SNSE

Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)

· Issued by Sensei Biotherapeutics, Inc.

Summary by 6ix AI

Sensei Biotherapeutics, a clinical-stage biotechnology company developing cancer treatments, granted three new employees options to buy a total of 19,300 shares of its common stock, effective June 1, 2026, as an inducement to join the company.

Key details

  • The options were granted by the Compensation Committee of Sensei's Board of Directors under the company's 2026 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(4), a rule that allows stock awards to new hires as an incentive to join.
  • The exercise price is $19.79 per share, equal to the closing price of Sensei's common stock on June 1, 2026.
  • 25% of the shares in each award vest on the first anniversary of the employee's start date, with the rest vesting in 36 substantially equal monthly installments after that.

What’s still pending

  • Vesting of each award depends on the employee's continued service with Sensei through each vesting date.

6ix AI wrote this summary from the release below and checked it against the release.

BOSTON - Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) announced that, effective on June 1, 2026, the Compensation Committee of Sensei's Board of Directors granted three new employees options to purchase an aggregate of 19,300 shares of the Company's common stock in connection with their employment (collectively, the 'Option Awards').

The Option Awards were granted pursuant to the Company's 2026 Inducement Plan as a material inducement to the individuals entering employment with Sensei in accordance with Nasdaq Listing Rule 5635(4).

The Option Awards have an exercise price of $19.79, which is equal to the closing price of Sensei's common stock on June 1, 2026, and will vest, with respect to 25% of the shares subject to each such award, on the first anniversary of the applicable employee's start date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter, in each case subject to such employee's continued service with Sensei through each such vesting date.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) is a clinical-stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients. Following the acquisition of Faeth Therapeutics, Sensei's lead program is PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. Sensei is also completing a Phase 1/2 trial of solnerstotug, its V-domain Ig suppressor of T cell activation (VISTA) inhibitor, in patients with advanced solid tumors.

Sensei intends to use its website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

Contact:

Stephanie Ascher

Email: [email protected]

Patrick Schmidt

Email: [email protected]

(C) 2026 Electronic News Publishing, source ENP Newswire

Sensei Biotherapeutics, Inc. on 6ix

Story so far

Earlier from Sensei Biotherapeutics

Later from Sensei Biotherapeutics

All Sensei Biotherapeutics news releases